Vistusertib

Drug Profile

Vistusertib

Alternative Names: AZD 2014

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Diffuse large B cell lymphoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase I/II Breast cancer; Fallopian tube cancer; Glioblastoma; Peritoneal cancer
  • Phase I Prostate cancer
  • No development reported Advanced breast cancer
  • Discontinued Renal cancer

Most Recent Events

  • 01 Dec 2016 AstraZeneca completes a phase IIa trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA, Germany and Spain (PO) (NCT02403895)
  • 14 Sep 2016 AstraZeneca withdraws the modular phase I/IIa INHIBITOR trial for Diffuse large B-cell lymphoma (Second-line therapy or greater, Combination therapy) prior to enrolment in USA (PO) (NCT02780830)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Advanced-breast-cancer(Combination therapy, Metastatic disease) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top